For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
How has the persistent epithelial defect management grown historically, and what trends indicate future expansion?
The persistent epithelial defect management market size has grown rapidly in recent years. It will grow from $7.92 billion in 2024 to $9.29 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to increased research activities, higher demand for hospitals, increasing prevalence of ocular surface disorders, increasing prevalence of eye disorders, aging population.
The persistent epithelial defect management market size is expected to see rapid growth in the next few years. It will grow to $17.35 billion in 2029 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to increased partnerships and collaborations, growing awareness and education, focus on value based care, rising prevalence of conditions like diabetes and hypertension, early intervention and management. Major trends in the forecast period include technological advancements, increasing demand of innovative treatment types, advanced treatment modalities, availability of advanced surgical tools and techniques, innovative drugs.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21256&type=smp
Which key factors are driving the expansion of the persistent epithelial defect management industry?
The increasing prevalence of eye disorders is expected to propel the growth of the persistent epithelial defect management market going forward. Eye disorders refer to a broad range of medical conditions that affect the structure, function, or health of the eyes, leading to vision impairment, discomfort, or potential blindness. The prevalence of eye disorders is driven by factors such as aging populations, prolonged screen time, and environmental changes. Persistent epithelial defect management is essential for treating eye disorders, as it promotes healing, alleviates inflammation, and prevents complications such as infection or scarring. For instance, in December 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, the overall pooled prevalence of childhood myopia was 5.23% in 2023, with a significantly higher rate among females (4.90%) compared to males (3.94%). Therefore, the increasing prevalence of eye disorders drives the growth of the persistent epithelial defect management market.
Rise In Eye Surgeries Driving The Growth Of The Market
The rise in eye surgeries is expected to propel the growth of the persistent epithelial defect management market going forward. Eye surgeries refer to medical procedures performed on the eye to correct vision problems, treat diseases, or repair injuries. The rise in eye surgeries is attributed to the increasing prevalence of eye disorders such as cataracts, glaucoma, and refractive errors, advancements in surgical techniques, and the growing adoption of minimally invasive procedures. Persistent epithelial defect management enhances eye surgeries by promoting corneal healing, reducing complications, and improving visual outcomes through targeted treatments that support epithelial regeneration. For instance, in 2023, according to the Eye Bank Association of America, a US-based transplant association, domestic keratoplasty procedures grew by 2.7%, increasing from 49,597 in 2022 to 50,925 in 2023. Therefore, the rise in eye surgeries is driving the growth of the persistent epithelial defect management market.
How is the persistent epithelial defect management market segmented by product, application, and end-user?
The persistent epithelial defect management market covered in this report is segmented –
1) By Disease Type: Epithalial Or Limbal, Inflammatory Disease, Neurotrophic Disease, Other Disease Types
2) By Distribution Channel: Direct Sales, Online Pharmacy, Retail Pharmacy, Hospitals
3) By End User: Hospital Or Clinical Laboratories, Physician Offices, Reference Laboratories, Other End Users
Subsegments:
1) By Epithelial Or Limbal: Limbal Stem Cell Deficiency (LSCD), Limbal Transplantation, Conjunctival Transplantation
2) By Inflammatory Disease: Dry Eye Syndrome, Allergic Conjunctivitis, Uveitis
3) By Neurotrophic Disease: Herpes Simplex Virus (HSV) Keratitis, Diabetic Neuropathy, Neurotrophic Keratopathy
4) By Other Disease Types: Chemical Burns, Trauma-Induced Defects, Congenital Corneal Opacities
View The Full Market Report:
Which sustainability trends are emerging in the persistent epithelial defect management market?
Major companies operating in the persistent epithelial defect management market are focusing on developing innovative therapies, such as secretome therapy, to accelerate healing and improve treatment outcomes for persistent epithelial defects. Secretome therapy refers to using bioactive molecules secreted by cells, such as proteins, lipids, and extracellular vesicles, to promote tissue repair, modulate immune responses, and treat various diseases. For instance, in April 2023, Kala Pharmaceuticals Inc., a US-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) Fast Track Designation for KPI-012, a human MSC-S therapy for persistent corneal epithelial defect. The drug’s multifactorial mechanism of action aims to address all underlying etiologies of persistent epithelial defect management by promoting corneal healing through bioactive molecules such as growth factors, protease inhibitors, and neurotrophic factors.
Which leading companies are dominating the persistent epithelial defect management market landscape?
Major companies operating in the persistent epithelial defect management market are AbbVie Inc., Novartis AG, Johnson & Johnson Vision, RegeneRx Biopharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Alcon Inc., Bausch Health Companies Inc., Hoya Vision Care, Santen Pharmaceutical Co. Ltd., Recordati Rare Diseases Inc., Dompé Farmaceutici S.p.A., Lumenis Ltd., TissueTech Inc., Ocular Therapeutix Inc., Oculus Surgical Inc., Amber Ophthalmics Inc., Noveome Biotherapeutics Inc., OcuNexus Therapeutics Inc., Lux Bio Inc., Eyenovia Inc.
Which geographic areas are expected to offer the highest growth opportunities in thepersistent epithelial defect management market?
North America was the largest region in the persistent epithelial defect management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the persistent epithelial defect management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Persistent Epithelial Defect Management Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21256
Need Customized Data On Persistent Epithelial Defect Management Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=21256&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
